0000000000235946

AUTHOR

Fabrizio Zanconati

showing 9 related works from this author

Breast Cancer Organoids Model Patient-Specific Response to Drug Treatment

2020

Tumor organoids are tridimensional cell culture systems that are generated in vitro from surgically resected patients&rsquo

0301 basic medicineCancer ResearchMechanotransductionBreast cancer; Dasatinib; Drug testing; Heterogeneity; Mechanotransduction; Patient‐derived tumor organoids; Statin; YAPPatient‐derived tumor organoidCellDasatinibDrug resistanceSettore MED/08 - Anatomia PatologicaBiologylcsh:RC254-282Article03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerbreast cancermedicineOrganoidSettore MED/05 - Patologia Clinicadasatinibdrug testingmechanotransductionpatient-derived tumor organoidsGenetic heterogeneitystatinStatinDrug testingBreast cancerDasatinib Drug testing Drug testing Heterogeneity Patient‐derived tumor organoids Statin YAPmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensIn vitroDasatinib030104 developmental biologymedicine.anatomical_structureOncologyCell culture030220 oncology & carcinogenesisCancer researchPatient‐derived tumor organoidsYAPHeterogeneityheterogeneitymedicine.drugCancers
researchProduct

Prognostic Implications of the Complement Protein C1q in Gliomas

2019

The contribution of the complement system in the pathophysiology of brain cancers has been recently considered in light of its well-known involvement in carcinogenesis. Complement system represents an important component of the inflammatory response, which acts as a functional bridge between the innate and adaptive immune response. C1q, the first recognition subcomponent of the complement classical pathway, has recently been shown to be involved in a range of pathophysiological functions that are not dependent on complement activation. C1q is expressed in the microenvironment of various types of human tumors, including melanoma, prostate, mesothelioma, and ovarian cancers, where it can exer…

Male0301 basic medicinemedicine.disease_causePathogenesisbioinformatics analysis; C1q complement; gliomas; prognostic significance of C1q; survival probability0302 clinical medicinegliomaTumor MicroenvironmentImmunology and AllergyComplement C1qbioinformatics analysiOriginal ResearchSettore MED/27 - NeurochirurgiaBrain NeoplasmsMelanomaBioinformatics analysiGliomaPrognosisAcquired immune systemNeoplasm ProteinsGene Expression Regulation NeoplasticBioinformatics analysisFemalePrognostic significance of C1q.Databases Nucleic Acidlcsh:Immunologic diseases. Allergybioinformatics analysisImmunologyprognostic significance of C1qBiology03 medical and health sciencesClassical complement pathwayC1q complementGliomaBiomarkers TumormedicineHumanssurvival probabilitySurvival probabilityGliomasC1q complementComplement C1qmedicine.diseaseComplement systemgliomas030104 developmental biologyCancer researchlcsh:RC581-607Carcinogenesis030215 immunologyFrontiers in Immunology
researchProduct

Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth

2017

C1q is the first recognition subcomponent of the complement classical pathway, which acts towards the clearance of pathogens and apoptotic cells. C1q is also known to modulate a range of functions of immune and non-immune cells, including their involvement in placental development and sensorial synaptic pruning. We have recently shown that C1q can promote tumour by encouraging their adhesion, migration and proliferation in addition to angiogenesis and metastasis. In this study, we have examined the role of C1q in the microenvironment of malignant pleuric mesothelioma (MPM), a rare form of cancer commonly associated with exposure to asbestos. We found that C1q was highly expressed in all MPM…

lcsh:Immunologic diseases. Allergy0301 basic medicineComplement system; Malignant pleural mesothelioma; Hyaluronic acid; Mesothelioma cells; C1q; CancerAngiogenesisMPMp38 mitogen-activated protein kinasesImmunologyHAchemical and pharmacologic phenomenaBiologyMetastasisMesothelioma cell03 medical and health sciencesClassical complement pathwaychemistry.chemical_compound0302 clinical medicineImmune systemhyaluronic acidHyaluronic acidmedicinemalignant pleural mesotheliomacancerImmunology and AllergyCell adhesioncomplement systemC1qcomplement system; MPM; HA; Mesothelioma cells; C1q and cancerOriginal ResearchC1q and cancermedicine.diseaseComplement system030104 developmental biologyC1q; Cancer; Complement system; Hyaluronic acid; Malignant pleural mesothelioma; Mesothelioma cells; Immunology and Allergy; Immunologychemistrymesothelioma cells030220 oncology & carcinogenesisImmunologyCancer researchlcsh:RC581-607Frontiers in Immunology
researchProduct

Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility

2017

The importance of the immune system as a potent anti-tumor defense has been consolidated in recent times, and novel immune-related therapies are today demonstrating a strong clinical benefit in the setting of several solid neoplasms. Tumor-infiltrating lymphocytes reflect the attempt of the host to eradicate malignancies, and during the last decades, they have been shown to possess an interesting prognostic utility for breast cancer, especially in case of HER2 positive and triple-negative molecular subtypes. In parallel, the clinical evaluation of tumor-infiltrating lymphocytes has been shown to effectively predict treatment outcomes in both neoadjuvant and adjuvant settings. Currently, tu…

Tumor-infiltrating lymphocytes; breast cancer; cancer immunotherapy0301 basic medicineOncologyCA15-3medicine.medical_specialtymedicine.medical_treatmentCA 15-3Tumor-infiltrating lymphocyteBreast NeoplasmsTumor-infiltrating lymphocytes03 medical and health sciencesLymphocytes Tumor-Infiltratingbreast cancer0302 clinical medicineImmune systemBreast cancerCancer immunotherapyInternal medicinemedicineHumansRC254-282cancer immunotherapyTumor-infiltrating lymphocytesbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerGeneral MedicinePrognosismedicine.diseaseNeoadjuvant TherapyTreatment Outcome030104 developmental biologyImmunoediting030220 oncology & carcinogenesisFemalebusinessTumor Biology
researchProduct

C1q–Ha matrix regulates the local synthesis of hyaluronan in malignant pleural mesothelioma by modulating has3 expression

2021

Increased hyaluronic acid (HA) production is often associated with cancer progression. In malignant pleural mesothelioma (MPM), HA is found at elevated levels in pleural effusions and sera of patients, and it has been widely debated whether MPM cells are able to produce HA by themselves or through the release of growth factors stimulating other cells. Another key component of the MPM microenvironment is C1q, which can act as a pro-tumorigenic factor favoring cell adhesion, migration and proliferation. The aim of the current study was to prove that MPM primary cells are able to synthesize HA and to inquire the stimulus given by C1q&ndash

hyaluronan synthaseCancer ResearchComplement systemHyaluronic acidMalignant pleural mesotheliomahyaluronan synthasesMatrix (biology)lcsh:RC254-282Articlechemistry.chemical_compoundImmune systemHyaluronan synthaseHyaluronic acidhyaluronic acidmalignant pleural mesotheliomacancertumor microenvironmentC1q; Cancer; Complement system; HAS3; Hyaluronan synthases; Hyaluronic acid; Immune system; Malignant pleural mesothelioma; Tumor microenvironmenttumor microenvironment.Cell adhesioncomplement systemC1qCancerTumor microenvironmentMessenger RNAChemistrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensComplement systemimmune systemHAS3Immune systemOncologyTumor microenvironmentCancer researchIntracellular
researchProduct

Pathological significance and prognostic value of surfactant protein D in cancer

2018

Surfactant protein D (SP-D) is a pattern recognition molecule belonging to the Collectin (collagen-containing C-type lectin) family that has pulmonary as well as extra-pulmonary existence. In the lungs, it is a well-established opsonin that can agglutinate a range of microbes, and enhance their clearance via phagocytosis and super-oxidative burst. It can interfere with allergen–IgE interaction and suppress basophil and mast cell activation. However, it is now becoming evident that SP-D is likely to be an innate immune surveillance molecule against tumor development. SP-D has been shown to induce apoptosis in sensitized eosinophils derived from allergic patients and a leukemic cell line via …

Male0301 basic medicineLung NeoplasmsDatasets as Topic0302 clinical medicineEpidermal growth factorNeoplasmsImmunology and AllergyRNA NeoplasmOriginal ResearchCancerOvarian NeoplasmsInnate immunitySurfactant protein DBioinformatics analysiPrognosisPulmonary Surfactant-Associated Protein DImmunohistochemistryTumor microenvironment030220 oncology & carcinogenesisAdenocarcinomaFemaleCancersBreast NeoplasmHumanlcsh:Immunologic diseases. AllergyPrognosiImmunologyBreast NeoplasmsBiology03 medical and health sciencesImmune systemBioinformatics analysisStomach NeoplasmsStomach NeoplasmBiomarkers TumormedicineHumansComputer SimulationLung cancerTumor microenvironmentOvarian NeoplasmComputational BiologySurfactant protein DCancermedicine.diseaseSurvival AnalysisLung NeoplasmImmune surveillance030104 developmental biologyCancer researchNeoplasmBioinformatics analysis; Cancers; Immune surveillance; Immunohistochemistry; Innate immunity; Surfactant protein D; Tumor microenvironment; Immunology and Allergy; Immunologylcsh:RC581-607Ovarian cancer
researchProduct

Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs

2015

Nucleic acid based drugs (NADBs) are short DNA/RNA molecules that include among others, antisense oligonucleotides, aptamers, small interfering RNAs and micro-interfering RNAs. Despite the different mechanisms of actions, NABDs have the ability to combat the effects of pathological gene expression in many experimental systems. Thus, nowadays, NABDs are considered to have a great therapeutic potential, possibly superior to that of available drugs. Unfortunately, however, the lack of effective delivery systems limits the practical use of NABDs. Due to their hydrophilic nature, NABDs cannot efficiently cross cellular membrane; in addition, they are subjected to fast degradation by cellular and…

Cellular membranePolymersAntisense oligonucleotides aptamers carbon nanotubes exososomes liposomes miRNA polymers siRNAAptamerClinical BiochemistryNanotechnologyAnimals; Humans; Lipids; Nanoparticles; Nanotubes Carbon; Nucleic Acids; Polymers; Drug Delivery SystemsBiologyNanoparticleDrug Delivery SystemsNucleic AcidsAnimalsHumansAvailable drugsPolymerPharmacologyNanotubesNucleic AcidAnimalNanotubes CarbonCarbon chemistryRNALipidLipidsCarbonSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoAntisense oligonucleotidesNucleic acidNanoparticlesHuman
researchProduct

Is the Complement Protein C1q a Pro- or Anti-tumorigenic Factor? Bioinformatics Analysis Involving Human Carcinomas

2019

C1q is the first subcomponent of the classical pathway of the complement system and belongs to the C1q/Tumor Necrosis Factor superfamily. C1q can perform a diverse range of immune and non-immune functions in a complement-dependent as well as -independent manner. Being a pattern recognition molecule of the innate immunity, C1q can recognize a number of self, non-self and altered-self ligands and bring about effector mechanisms designed to clear pathogens via opsonisation and inflammatory response. C1q is locally synthesized by macrophages and dendritic cells, and thus, can get involved in a range of biological processes, such as angiogenesis and tissue remodeling, immune modulation, and immu…

lcsh:Immunologic diseases. Allergy0301 basic medicinetumorLung NeoplasmsMicroenvironmentPrognosiImmunologyComplementBreast Neoplasmschemical and pharmacologic phenomenaKaplan-Meier EstimateBiology03 medical and health sciencesClassical complement pathway0302 clinical medicineImmune systemimmune system diseasesmedicineHumansImmunology and Allergycomplementclassical pathwayskin and connective tissue diseasesC1qOriginal ResearchTumorInnate immune systemEffectorComplement C1qComputational BiologyCancerPrognosismedicine.diseasemicroenvironmentKidney NeoplasmsComplement systemClear cell renal cell carcinomaC1q; Classical pathway; Complement; Microenvironment; Prognosis; Tumor030104 developmental biologyClassical pathwayCancer researchAdenocarcinomaprognosislcsh:RC581-607030215 immunologyFrontiers in Immunology
researchProduct

Targeted delivery of siRNAs against hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer

2021

Given the lack of effective treatments for Hepatocellular carcinoma (HCC), the development of novel therapeutic approaches is very urgent. Here, siRNAs were delivered to HCC cells by a synthetic polymer containing α,β-poly-(N-2-hydroxyethyl)-D,L-aspartamide-(PHEA) derivatized with diethylene triamine (DETA) and bearing in the side chain galactose (GAL) linked via a polyethylene glycol (PEG) to obtain (PHEA-DETA-PEG-GAL, PDPG). The GAL residue allows the targeting to the asialo-glycoprotein receptor (ASGPR), overexpressed in HCC cells compared to normal hepatocytes. Uptake studies performed using a model siRNA or a siRNA targeted against the enhanced green fluorescence protein, demonstrated …

Small interfering RNACarcinoma HepatocellularPolymersHepatocellular carcinomaCellASGPR targeted delivery; E2F1; Eukaryotic elongation Factor 1A; Hepatocellular carcinoma; siRNAPharmaceutical Science02 engineering and technologyEukaryotic elongation Factor 1AMice03 medical and health sciencesIn vivomedicineAnimalsE2F1RNA Small InterferingReceptor030304 developmental biology0303 health sciencesChemistryLiver NeoplasmsASGPR targeted deliveryGalactose021001 nanoscience & nanotechnologymedicine.diseasedigestive system diseasesEukaryotic translation elongation factor 1 alpha 1In vitromedicine.anatomical_structureE2F1Settore CHIM/09 - Farmaceutico Tecnologico ApplicativoHepatocellular carcinomasiRNACancer research0210 nano-technology
researchProduct